title: [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
abstract: Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.
authors.affiliation: Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C. charlotte.steffensen@ki.au.dk.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Steffensen
authors.forename: Merete Lund
authors.initials: ML
authors.lastname: Mægbæk
authors.forename: Peter
authors.initials: P
authors.lastname: Laurberg
authors.forename: Marianne
authors.initials: M
authors.lastname: Andersen
authors.forename: Caroline
authors.initials: C
authors.lastname: Kistorp
authors.forename: Helene
authors.initials: H
authors.lastname: Nørrelund
authors.forename: Jakob
authors.initials: J
authors.lastname: Dal
authors.forename: Jens Otto Lunde
authors.initials: JO
authors.lastname: Jørgensen
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D006966:Hyperprolactinemia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010300:Parkinson Disease / Q000188:drug therapy; D014463:Ultrasonography
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline